NVOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Novo Integrated Sciences's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Novo Integrated Sciences Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Novo Integrated Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:
For example, Novo Integrated Sciences's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Feb. 2024 (Change) | * | Current CPI (Feb. 2024) |
= | -0.097 | / | 130.9299 | * | 130.9299 | |
= | -0.097 |
Current CPI (Feb. 2024) = 130.9299.
Novo Integrated Sciences Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -0.309 | 99.695 | -0.406 |
201406 | -0.205 | 100.560 | -0.267 |
201409 | -0.178 | 100.428 | -0.232 |
201412 | -0.219 | 99.070 | -0.289 |
201503 | -0.139 | 99.621 | -0.183 |
201506 | -0.403 | 100.684 | -0.524 |
201509 | -0.231 | 100.392 | -0.301 |
201512 | -0.068 | 99.792 | -0.089 |
201603 | -0.095 | 100.470 | -0.124 |
201606 | -0.205 | 101.688 | -0.264 |
201609 | -0.089 | 101.861 | -0.114 |
201612 | -0.102 | 101.863 | -0.131 |
201703 | -0.238 | 102.862 | -0.303 |
201708 | -0.222 | 103.587 | -0.281 |
201711 | -0.176 | 104.072 | -0.221 |
201802 | -0.079 | 105.052 | -0.098 |
201805 | -0.189 | 106.148 | -0.233 |
201808 | -0.091 | 106.383 | -0.112 |
201811 | -0.114 | 106.338 | -0.140 |
201902 | -0.140 | 106.649 | -0.172 |
201905 | -0.044 | 108.048 | -0.053 |
201908 | -0.132 | 108.245 | -0.160 |
201911 | -0.133 | 108.519 | -0.160 |
202002 | -0.122 | 109.139 | -0.146 |
202005 | 0.066 | 108.175 | 0.080 |
202008 | -0.007 | 109.662 | -0.008 |
202011 | -0.063 | 109.793 | -0.075 |
202102 | -0.119 | 110.968 | -0.140 |
202105 | 0.059 | 113.576 | 0.068 |
202108 | -0.281 | 115.421 | -0.319 |
202111 | -0.327 | 117.269 | -0.365 |
202202 | -0.808 | 119.703 | -0.884 |
202205 | -1.190 | 123.323 | -1.263 |
202208 | 0.218 | 124.958 | 0.228 |
202211 | -0.082 | 125.607 | -0.085 |
202302 | -0.111 | 126.928 | -0.115 |
202305 | -0.060 | 128.314 | -0.061 |
202308 | -0.015 | 129.538 | -0.015 |
202311 | -0.129 | 129.548 | -0.130 |
202402 | -0.097 | 130.930 | -0.097 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Novo Integrated Sciences (NAS:NVOS) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Novo Integrated Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarfaraz Ali | director | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Robert Letterio Oliva | director | 115 BELFIELD RD, TORONTO A6 L0J 1C0 |
Sterling M. Jimenez | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Michael Ross Pope | director | 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043 |
Alex Flesias | director | 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7 |
Michael Joseph Gaynor | director | 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0 |
Robert Mattacchione | director, 10 percent owner, officer: Chief Executive Officer | 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1 |
Pierre Joseph Dalcourt | director, 10 percent owner | 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0 |
Christopher Mehlin David | director, officer: President | 10425 SE 22ND ST., BELLEVUE WA 98004 |
Thomas Edward Bray | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Rebecca Aw Mcdonald | officer: Chief Accounting Officer | 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724 |
James Jr Teters | director | 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724 |
Phyllis Rouse | officer: secretary | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Jay Hilden | officer: President & CEO | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Robert Adamo | director | 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724 |
From GuruFocus
By Business Wire • 10-24-2023
By Business Wire • 11-06-2023
By Business Wire • 07-17-2023
By Business Wire • 11-24-2023
By Business Wire Business Wire • 10-25-2022
By Business Wire • 08-15-2023
By Business Wire Business Wire • 11-30-2022
By Business Wire • 12-05-2023
By Business Wire • 08-15-2023
By Business Wire • 09-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.